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IT has been shown previously that cultured human venous
and arterial endothelial cells (EC) bind Clq in a time- and
dose-dependent manner. Cultured human endothelial
cells express an average number of 5.2 x 10 binding
sites/cell. In the present study the putative receptor for Clq
(ClqR) was isolated from the membranes of 1-5 x 109
human umbilical cord EC by affinity chromatography on
Clq-Sepharose. During isolation, ClqR was detected by
its capacity to inhibit the lysis of EAClq in Clq-deficient
serum. The eluate from Clq-Sepharose was concentrated,
dialysed and subjected to QAE-A50 chromatography and
subsequently to gel filtration on HPLC-TSK 3000. ClqR
filtered at an apparent molecular weight of 60 kDa.
Purified ClqR exhibited an apparent molecular weight of
55-62 kDa in the unreduced state and a molecular weight
of 64-68 kDa in reduced form. Two IgM monoclonal
antibodies (mAb) D3 and D5 were raised following
immunization of mice with purified receptor preparations.
Both monoclonal antibodies increased the binding of
SI-Clq to endothelial cells but F(ab’)2 anti-ClqR mAb
inhibited the binding of aSI-Clq to EC in a dose-
dependent manner. The D3 mAb recognized a band of
54-60 kDa in Western blots of membranes of human EC
and polymorphonuclear leukocytes. Previously, the
authors showed that Clq induces the binding of
IgM-containing immune complexes to EC. Therefore, it
was hypothesized that during a primary immune response
generation of IgM-IC may occur, resulting in binding and
activation of C1, dissociation of activated C1 by C1
inhibitor and subsequent interaction of IgM-IC bearing
Clq with EC-ClqR.
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Introduction
The endothelial cell layer represents a barrier
between the circulation and the vessel wall, and may
play an important role in processes which mediate
inflammation. The role of the vascular endothelium
in the deposition of immune complexes (IC) in vivo
is not clear. Most IC are able to trigger receptor
mediated activation of various cells such as
monocytes and granulocytes. This may occur via
Fc receptors alone or via Fc receptors in synergy
with complement receptors. Receptors for the Fc2
portion of IgG have been described on various
cells, and more recently the authors have shown
that rat liver endothelial cells express functional
receptors for the Fc2 region of IgG in situ.
2
Furthermore, receptors for the Fc2 region of IgG
and Chb were found on Herpes simplex virus
(HSV)-infected umbilical cord venous endothelial
cells. Later studies have established that these
receptors are encoded by the viral genome. 4’5 The
first indication that another complement receptor
(C) 1993 Rapid Communications of Oxford ktd
was present on endothelial cells, namely a receptor
for Clq, was obtained by Linder
6 and further
established by other, v The authors have described
previously that human umbilical cord venous and
arterial EC express substantial numbers of ClqR.
More insight into the binding of Clq to a variety
of somatic and cultured ceils and further identifica-
tion of a putative ClqR has been obtained more
recently.
9-12 In the present study ClqR was purified
from the membranes of cultured umbilical cord EC
and it appears to be closely related to Clq receptors




Endothelial cell cultures: Human umbilical cord vein
endothelial cells (HUVEC) were isolated and
cultured as described. 8’.1v In short, umbilical cord
veins were flushed with phosphate buffered saline
and incubated with a collagenase solution (1 mg/ml,
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Sigma, St. Louis, MO) for 20 min at 37C. Cells
were cultured on 1% gelatin treated plastic culture
flasks (T75, Greiner) in M199 with Earls salts
(Seromed, Biochrom KG, Berlin, Germany) supple-
mented with 20% heat inactivated normal human
serum and endothelial cell growth factor
18 isolated
from bovine hypothalamus. Cells were subcultured
after trypsinization by distributing them into three
new culture flasks. For the isolation of ClqR
generally 1-5 109 HUVEC were used from
passage 4-7. In most cases endothelial cells obtained
from three to four umbilical cords were pooled.
HUVEC were routinely examined by indirect
immunofluorescence employing a rabbit poly-
clonal anti-human WF antibody (gift of Professor
R. Bertina, Leiden).
Isolation of ClqR was also performed from the
membranes of the endothelial hybridoma cell line
EAhy.926. This line was obtained by fusing
human umbilical vein endothelial cells with the
human cell line A549 (human lung carcinoma)
and was maintained in culture as described
previously.
19
Solubilization of HUVEC and EAhy.926: Confluent
layers of cells were rinsed with sterile PBS, the cells
detached subsequently by incubation for 30 min at
0C in PBS containing 10 mM EDTA, and washed
three times by centrifugation at 150 g and
resuspension in ice-cold water containing 5 mM
EDTA. Usually, 1-5 109 cells were resuspended
in 5 ml water, and frozen at -80C. Thereafter the
cells were frozen and thawed a total of five times.
The resultant mixture was centrifuged for 10 min
at 15 000 "
and the pellet containing mainly cell
membranes washed three times with ice-cold PBS
containing 5 mM EDTA. The washed cell mem-
brane pellet was finally resuspended in 2 ml lysis
buffer composed of 5 mM sodium phosphate, 5 mM
EDTA, 150 mM NaC1, 10 mM EACA and 0.5 mM
PMSF, pH 7.5 and containing 1% nonidet P40.
After incubation for 60 min at 37C with vigorous
shaking, the mixture was centrifuged for 20 min at
30 000 g and the supernatant dialysed against
lysis buffer containing 0.1% NP40.
Purification of ClqR: Endothelial cell membrane
lysates were loaded on a column of 4ml
Sepharose-Clq equilibrated in PBS containing
0.5 mM PMSF, 5 mM EDTA and 0.1% NP40,
pH 7.5. Clq was isolated from pooled human serum
as described previously
2 and 3 mg of Clq was
coupled to 1 ml of packed Sepharose. After
vigorous washing bound ClqR was liberated from
the column using 1 M NaC1. Protein content in the
fractions was measured by the Lowry method and
conductivity was assessed at 4C. ClqR was assayed
in the fractions using a haemolytic assay. The
fractions containing ClqR activity were pooled,
dialysed against 5 mM PMSF and subjected to ion
exchange chromatography on a 1.5 10cm
QAE-A50 Sephadex column equilibrated in dialysis
buffer. Bound activity was stripped from the
column with dialysis buffer containing 0.65 M
NaC1. ClqR activity was pooled, freeze dried,
resuspended in 250/1 PBS containing 5 mM EDTA
and 0.5 mM PMSF and after filtration on millipore
0.2 subjected to gel filtration on TSK 3000-
HPLC. Fractions of 0.3 ml/min were collected and
assessed for ClqR activity.
Assay for ClqR haemotic activity: Sheep erythrocytes
(E) sensitized with optimal concentrations of rabbit
IgG anti-E were prepared and incubated with a
suboptimal concentration of Clq, and washed at
4C with GVB2+. To assay for ClqR haemolytic
activity, tubes containing 1 107 EAClq in 100/1
DGVB + + were incubated with dilutions of
fractions from columns for 30 min at 0C and there-
after 0.1 ml Clq deficient serum diluted 1/50 in
DGVB++ was added to each tube followed by
incubation for another 60 min at 37C. Percent
haemolysis was determined following addition of
1.5 ml 0.15 M NaC1 and centrifugation. Appropri-
ate controls for reagent blank and input were
included in each assay. The amount of Clq chosen
to prepare EAClq was such that EAClq in Clq
deficient serum caused approximately 60-70% lysis
of the ceils.
Radioiodination procedures: TSK 3000-HPLC-derived
pools of ClqR were iodinated using 100 Ci NaleSI
(Amersham) as described previously.
21 Excess free
125I was removed by passing the reaction mixture
over a 0.5 5cm Dowex 1-8 column equi-
librated in PBS containing 1% glycerol and 0.05%
NP40.
Surface iodination of intact HUVEC or purified
PMN2 was performed with 1 107 cells in 1 ml
PBS at 22C by addition of 0.5 mCi Na12I, 60 #1
lactoperoxidase (1 mg/ml), and three sequential
additions (10/1 each) of H202 of 0.003% every
10-20 s. Thereafter the cells were washed three
times by centrifugation and resuspension in PBS to
remove free 12sI, and finally solubilized in lysis
buffer.
SDS-polyacrylamide gel electrophoresis (SDS-PA GE)
SDS-PAGE was performed using 7.5% poly-
acrylamide gels.
23 Samples were mixed with an
equal volume of 0.2 M Tris, 2% SDS, pH 8.0 with
and without 10 mM 2fl-mercaptoethanol and boiled
for 5 min. Gels were stained with Coomassie
brilliant blue, dried, and subjected to autoradio-
graphy using X-ray film.
Western blot analysis was performed as described
previously.
24 Five and 10 #g samples of solubilized
membranes were subjected to SDS-PAGE, blotted
onto nitrocellulose, reacted with monoclonal
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antibodies or isotype controls, washed and bound
antibodies reacted with biotinylated goat antimouse
Ig, followed by incubation with streptavidin
alkaline phosphatase (Zymed Laboratories Inc.) for
1 h, and detected with naphthol AS-MX phosphate
(Sigma, St. Louis, MO) and Fast Red (Sigma) as
substrate. Every incubation step was followed by a
15 min washing step in PBS-0.5% Tween 20.
Monoclonal antibodies: Spleen cells were obtained by
standard techniques from Balb/c mice immunized
with three weekly injections of 50/g quantities of
ClqR emulsified in complete Freund’s adjuvant.
The spleen cells were fused with non-secreting
SP 20 myeloma cells and the fused cells selected in
hypoxanthine-aminopterin-thymidine medium.
Culture supernatants of cell lines were screened by
ELISA for reactivity with purified ClqR from
HUVEC. From each positive well, individual
clones were prepared by adding 100/1 culture
medium containing 3 cells/ml to microtitre plates.
In this way two positive clones were selected (D3
and D5) for further analysis. Ascitis was prepared
in Balb/c mice following injection of 1 106 cells
per mouse. Limited proteolytic digestion of mouse
IgM was carried out by incubation of 1 mg/ml
solutions of D5 or control MoAb in 20 mM Tris,
150 mM NaC1, 20 mM cad2, pH 8 with 150 #g/ml
diphenyl carbamyl chloride (DPCC, Sigma) treated
trypsin (Sigma) for 5 h at 37C. Mercaptoethanol
was added to 10 mM and the solution incubated for
5min at 37C, followed by 15 #g/ml trypsin
inhibitor (Sigma) to stop the reaction and further
incubated for 5 min. Finally the mixture was made
up to 50mM iodoacetamide and left at room
temperature for 10 min. After dialysis 7S fragments
of IgM were obtained by gel filtration on Sepharose
4B. The 7S fragments were dialysed against sodium
acetate buffer pH 3.8 and treated with 1% pepsin
(w/w) for 16 h at 37C and the F(ab’)2 fragments
recovered after gel filtration on Sephadex G150.
Binding studies: The binding of 12SI-C1q to EC was
performed as described previously.
8 To determine
the effect of D3 and D5 on binding of 12SI-C1q to
EC, monolayers ofEC in 48-well culture wells were
incubated with 100 ng 2SI-Clq in RPMI-0.5% BSA
alone or in the presence of increasing concentra-
tions of purified F(ab’)2 D3 or D5 monoclonal
antibodies. As a control a nonspecific F(ab’)2 from
mouse IgM monoclonal antibody was used. After
incubation for 2 h at 4C, the wells were washed
and cell bound radioactivity assessed following lysis
of the cells with 100 1 1N NaOH for 1 h.
Results
The fractionation of detergent solubilized














FIG. 1. Affinity chromatography of detergent solubilized endothelial cell
membranes on Sepharose-Clq. Protein content (O-C)), conductivity
(--) and Clq-R activity (0-0) in the fractions is depicted. Fractions
148-162 were pooled for further purification on QAE-A50.
aflqnity chromatography on Sepharose-Clq is
shown in Fig. 1. Most of the protein was found in
the fall-through fractions, while only a small
amount of protein emerged from the column
between 11 and 14 mS. When the fractions from the
column were tested in dilutions of 1:10 for ClqR
function all the inhibitory activity was found to be
associated with the protein peak in the gradient.
Fractions 148-162 were pooled, dialysed and
fractionated further on a QAE-A50 Sephadex
column (Fig. 2). Very little detectable protein was
found in the fall-through fractions and more than
80% of ClqR functional activity could be eluted
from the QAE column with a step gradient of NaC1.
The major peak of ClqR activity was associated
with the main protein peak. To obtain some insight
into the size of ClqR, fractions 52-57 were pooled,
freeze dried and subjected to fractionation by HPLC
on a TSK 3000 column. ClqR activity, associated
with the only detectable protein peak, emerged
from the column with an apparent molecular weight
of 60 kDa. The fractions containing peak ClqR
activity were pooled, freeze dried and part of it
labelled with 2sI and analysed by SDS-PAGE and
autoradiography. Under non-reducing conditions
only one major band was seen with an apparent
molecular weight of 55-62 kDa. Under reducing
conditions the molecular weight was between





















FIG. 2. Anion-exchange chromatography of affinity purified ClqR on
QAE-A50. Protein content (O-C)), conductivity (--) and Clq-R
activity (O-I) are shown. Fractions 52-57 were pooled for further
analysis on TSK 3000-HPLC.






Table 1. Inhibition of lysis of EAC1Q by HUVEC C1QR and by
C1QR isolated from EAHY926 cells
Concentration
of ClqR Lysis of EAClq
(#g/ml) (Z) % Inhibition
HUVEC
EAHy926
0 1.31 4- 0.11
5 0.834- 0.10 36
10 0.36 4- 0.09 72
20 0.15 + 0.06 92
5 0.96 4- 0.11 26
10 0.41 4- 0.08 68
20 0.20 4- 0.06 85
al x 107 EAClq in 100 /1 DGVB were incubated with
dilutions of ClqR and Clq deficient human for 60 min at 37C
and subsequently assessed for lysis. Percent inhibition was





FIG. 3. SDS-PAGE of 1251-ClqR under reducing (R) and non-reducing
(U) conditions.
ClqR was also isolated from the membranes of
EAhy.926 using the same procedure as described
above for HUVEC-C1 qR. Comparable results were
obtained concerning the size and functional activity
of ClqR. Purified ClqR isolated from either
HUVEC or EAhy.96 were both able to inhibit lysis
of EAClq in a dose-dependent manner (Table 1).
ClqR induces inhibition of lysis of EAClq in Clq
deficient serum by binding to EAClq and
presumably by preventing the interaction with Clr
and Cls because EAClq preincubated with ClqR,
washed and subsequently exposed to Clq deficient
serum at 37C also exhibits inhibited lysis.
Monoclonal antibodies: Immunization of BALB/c mice
with purified HUVEC-ClqR and fusion of spleen
cells with Sp2/0 hybridoma cells yielded two
monoclonal cell lines, D5 and E3, both secreting
lgM. These two mAbs reacted only with ClqR and
not with Clq or its fragments (Table 2). Western
blot analysis revealed reactivity of D5 with one
maior molecule of approximately 60-64 kDa in
membrane lysates of both HUVEC and PMN (Fig.
4). In some experiments an additional faint band
was seen at 96-98 kDa, but this band was also seen
sometimes with isotype control mAb. In addition
some smaller molecular weight reaction products
were seen around 45 kDa. Since the antigen used
for immunization was purified by aflqnity chroma-
tography over Clq-Sepharose we also tested
whether D5 or E3 reacted with Clq, heat treated
C1 q, collagenous fragments of Clq or heads of Clq.
No significant reactivity of either mAb with Clq or
its fragments was found by ELISA.
Eect of monoclonal antibodies against ClqR on CIqR
mediated binding of 125I-C1q: To determine whether the
binding of 12SI-C1q to HUVEC could be influenced
by F(ab’)2 fragments of D5, HUVEC monolayers
of HUVEC were incubated with 1251-C1q in the
absence or presence of increasing concentrations of
mAb (Table 3). While 37.2% of 125I-Clq bound to
HUVEC in medium alone, 20-200/g F(ab’). anti
CIqR caused a dose-dependent inhibition of
binding. Full inhibition of binding of 12SI-C1q was
not observed in any of the three experiments
performed.
Table 2. Reactivity of D5 and E3 with ClqR or Clq and its fragments
Elisa wells coated with
Monoclonal
antibody C1 qR C1 q C1 q heads C1 q tails
D5 2.23 4- 0.14" 0.097 4- 0.013 0.099 4- 0.014 0.112 0.014
E3 1.78 4- 0.18 0.077 _+ 0.009 0.087 4- 0.007 0.113 -t- 0.026
Isotype 0.098 _+ 0.007 0.093 4- 0.012 0.112 4- 0.037 0.088 4- 0.041
control
Elisa wells were coated with #g/ml agent, washed and reacted with mAbs at a dilution of
1/500 in triplicate. Washed and bound antibody was detected with goat antimouse Ig-P0.
Mean OD492 + 2 S.D. of of three wells.
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FIG. 4. Western blot analysis of monoclonal antibody against C1 q-R. Five
(left lanes) or lO/g lysates of endothelial cell membranes (A) or PMN
membranes (B) were separated by electrophoresis, blotted onto
nitrocellulose and analysed for reactivity with D5-anti-ClqR.
Discussion
The present study extends the previous observa-
tions8 that human umbilical vein endothelial ceils
express a Clq receptor that has identity or is closely
related to ClqR described on lymphocytes. 9’1’14
ClqR was isolated by affinity chromatography on
Clq-Sepharose followed by further purification on
QAE-A50 and TSK 3000-HPLC and detected
during the isolation procedure using inhibition of
lysis of EAClq in Clq deficient serum. The first
step yielded material which was reasonably pure but
minor contaminants were mainly removed in the
QAE-A50 step. The purified ClqR filtered with an
apparent molecular weight of 60 kDa on TSK-3000.
Although the molecular weights for lymphocyte
ClqR have been reported to be in the range from
56-70 kDa,
25 these differences probably reflect the
different percentages of acrylamide used for
SDS-PAGE.
Monoclonal antibodies against the purified
endothelial cell ClqR were raised. These mono-
clonal antibodies reacted with purified ClqR from
HUVEC and from EAhy.926 cells. The purified
HUVEC ClqR was also shown to react with a
polyclonal antibody (kindly donated by Dr R. B.
Sim, Oxford) raised against the B-cell ClqR. On
the other hand it was found that while the D5 mAb
reacted also with B-cells and polymorphonuclear
leukocytes (PMN), the E3 mAb only reacts with
EC and PMN and not with B-cells, suggesting
differences in the epitopes of endothelial cell ClqR
and B-cell ClqR. On the other hand NHg-terminal
amino acid sequence analysis of the first fourteen
amino acids did not show any differences with the
Table 3. Inhibition of binding of 1251-Clq to endothelial cells
by F(ab’)2 anti-ClqR
Reagent Percent bound % Inhibition
1251_C1 q
251-C1 q + 20/g anti-C1 qR
251_C1 q + O0 #g anti-C1 qR
251-Clq + 200/g anti-ClqR
37.2 + 4.8
31.3 __+ 4.7 16.9
21.4 + 5.1 32.5
11.3 + 3.7 69.3
10 000 cpm of 1251-C1 q were used per well.
recently reported sequence of ClqR.
25 Further
studies are needed to elucidate these differences.
The D5 and E3 mAbs both recognized one major
band in membrane lysates of both HUVEC and
PMN. The size of ClqR from both these cell types
was well within the reported range size of ClqR.
26
While the D5 mAb was able to inhibit binding of
125I-Clq to EC the E3 mAb was much weaker in
this respect.
The results described in Table 1 indicate that
endothelial cell ClqR is able to interact with
immune-complex-bound Clq and prevent lysis of
EA-Clq in Clq deficient serum, suggesting that
assembly of an intact C1 on EAClq is prevented.
This mechanism may be of importance in viva to
regulate the degree of C1 activation in an early
phase of the immune response. In addition during
a primary immune response mainly IgM antibodies
are generated. There are no known cellular 19S IgM
receptors on human phagocytic cells, but by
binding and activation of C1, and subsequent
removal of activated Clr and Cls from the
IgM-immune complex-bound Clq, these types of
immune complexes may be trapped very rapidly on
vascular endothelial cells via ClqR, which, in turn,
may ingest these complexes, and prevent further
systemic immune complex-mediated inflammatory
responses.
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